Paul J Bröckelmann1, Dennis A Eichenauer, Tina Jakob, Markus Follmann, Andreas Engert, Nicole Skoetz. 1. Joint first authors; Department I of Internal Medicine, University Hospital Cologne; German Hodgkin Study Group (GHSG), University Hospital Cologne; Evidence-based Oncology, University Hospital Cologne; German Guideline Program in Oncology of the German Cancer Society, Berlin.
Abstract
BACKGROUND: Hodgkin lymphoma is the most common neoplasm in young adults, with an incidence of 2 to 3 cases per 100 000 persons per year. Risk-adapted chemotherapy and radiotherapy usually lead to cure. Finding ways to lessen the treatment- associated morbidity and mortality is a major goal of current research. METHODS: For the creation of an updated guideline (DKH grant number 111778), a systematic literature search was carried out in medical databases (MEDLINE, CENTRAL) and guideline databases (GIN) (search dates: January 2012 to June 2017). RESULTS: Results from 10 meta-analyses, 89 randomized and controlled trials, and 81 prospective or retrospective trials were evaluated. The use of positron emission tomography (PET) is strongly recommended in the initial diagnostic evaluation, as well as for the guidance of treatment in advanced stages. In early stages, two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and involved-site radiotherapy (IS-RT) at a dose of 20 Gy are recommended. For the treatment of intermedi- ate stages, two cycles of escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) + two cycles of ABVD and 30 Gy IS-RT are recommended. In advanced stages, two cycles of escalated BEACOPP are administered, and then PET is performed for the guidance of further treatment: two further cycles of escalated BEACOPP are recommended if the PET is negative and four further cycles if it is positive, followed by radiotherapy of PET- positive residual tumor tissue. The five-year survival of patients with Hodgkin lymphoma is 95%. In case of disease recurrence, high-dose chemotherapy followed by autologous stem-cell transplantation is performed, and targeted drugs including brentuxi- mab vedotin, nivolumab, and pembrolizuab are used. CONCLUSION: The highly favorable long-term prognosis of HL necessitates careful consideration of the intensity of treatment as well as thorough follow-up to enable the detection of late sequelae, such as second tumors or organ damage.
BACKGROUND:Hodgkin lymphoma is the most common neoplasm in young adults, with an incidence of 2 to 3 cases per 100 000 persons per year. Risk-adapted chemotherapy and radiotherapy usually lead to cure. Finding ways to lessen the treatment- associated morbidity and mortality is a major goal of current research. METHODS: For the creation of an updated guideline (DKH grant number 111778), a systematic literature search was carried out in medical databases (MEDLINE, CENTRAL) and guideline databases (GIN) (search dates: January 2012 to June 2017). RESULTS: Results from 10 meta-analyses, 89 randomized and controlled trials, and 81 prospective or retrospective trials were evaluated. The use of positron emission tomography (PET) is strongly recommended in the initial diagnostic evaluation, as well as for the guidance of treatment in advanced stages. In early stages, two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and involved-site radiotherapy (IS-RT) at a dose of 20 Gy are recommended. For the treatment of intermedi- ate stages, two cycles of escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) + two cycles of ABVD and 30 Gy IS-RT are recommended. In advanced stages, two cycles of escalated BEACOPP are administered, and then PET is performed for the guidance of further treatment: two further cycles of escalated BEACOPP are recommended if the PET is negative and four further cycles if it is positive, followed by radiotherapy of PET- positive residual tumor tissue. The five-year survival of patients with Hodgkin lymphoma is 95%. In case of disease recurrence, high-dose chemotherapy followed by autologous stem-cell transplantation is performed, and targeted drugs including brentuxi- mab vedotin, nivolumab, and pembrolizuab are used. CONCLUSION: The highly favorable long-term prognosis of HL necessitates careful consideration of the intensity of treatment as well as thorough follow-up to enable the detection of late sequelae, such as second tumors or organ damage.
Authors: Gordon H Guyatt; Andrew D Oxman; Regina Kunz; David Atkins; Jan Brozek; Gunn Vist; Philip Alderson; Paul Glasziou; Yngve Falck-Ytter; Holger J Schünemann Journal: J Clin Epidemiol Date: 2010-12-30 Impact factor: 6.437
Authors: Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz Journal: J Clin Oncol Date: 2017-04-25 Impact factor: 44.544
Authors: Karolin Behringer; Helen Goergen; Felicitas Hitz; Josée M Zijlstra; Richard Greil; Jana Markova; Stephanie Sasse; Michael Fuchs; Max S Topp; Martin Soekler; Stephan Mathas; Julia Meissner; Martin Wilhelm; Peter Koch; Hans-Walter Lindemann; Enrico Schalk; Robert Semrau; Jan Kriz; Tom Vieler; Martin Bentz; Elisabeth Lange; Rolf Mahlberg; Andre Hassler; Martin Vogelhuber; Dennis Hahn; Jörg Mezger; Stefan W Krause; Nicole Skoetz; Boris Böll; Bastian von Tresckow; Volker Diehl; Michael Hallek; Peter Borchmann; Harald Stein; Hans Eich; Andreas Engert Journal: Lancet Date: 2014-12-22 Impact factor: 79.321
Authors: Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: Boris Böll; Helen Goergen; Karolin Behringer; Paul J Bröckelmann; Felicitas Hitz; Andrea Kerkhoff; Richard Greil; Bastian von Tresckow; Dennis A Eichenauer; Carolin Bürkle; Sven Borchmann; Michael Fuchs; Volker Diehl; Andreas Engert; Peter Borchmann Journal: Blood Date: 2016-02-01 Impact factor: 22.113
Authors: Kunyan Sun; Qing Yu; Jiaxin Zhou; Hong Zhang; Li Gao; Lin Nong; Mangju Wang; Chengli Que Journal: Thorac Cancer Date: 2021-04-03 Impact factor: 3.500
Authors: Valentina Brancato; Marco Aiello; Roberta Della Pepa; Luca Basso; Nunzia Garbino; Emanuele Nicolai; Marco Picardi; Marco Salvatore; Carlo Cavaliere Journal: Diagnostics (Basel) Date: 2020-09-16